TB Screening and Treatment
Kenya is among 14 countries with the highest triple burden of TB, TB/HIV co-infection and Multi-drug Resistant TB (MDR-TB) globally. Out of 30 high burdened TB countries, Kenya is included in the list of 20 countries that contribute an estimated 85% of the global burden of disease in absolute numbers. This means that incident cases of TB exceed 10,000 while incident cases of TB/HIV coinfection and MDR-TB exceed 1,000 per year, according to the World Health Organization (WHO).
Yet, in the period 2010 to 2016, Kenya recorded the third highest rate of decline in TB incidence among high burden countries, at 6.9%, outpacing the global average rate of 1.4% per year (WHO, 2017).
TB occurs when a person exposed to TB bacteria and starts to develop signs and symptoms of TB e.g. Cough of any duration, fever, Night sweats, loss of weight, chest pain and shortness of breath.
TB can be diagnosed through clinical evaluation, Microbiology (Gene Xpert and sequencing), radiology (X-ray) and Tst (Tuberculin Skin Test). The main Aim of TB treatment: – Prevent long-time complications associated with TB, prevent relapse of the disease, prevent transmission of the disease and Prevent development of drug resistant TB. First line Anti TB drugs are prescribed for treatment of drug sensitive TB for six months. 1st line treatment is given to all drug sensitive new patients, relapse, previous failures and return after default depending on Drug susceptible TB results.
SWOP through community engagement has intensified TB case management with an aim to;
- Strengthen TB service delivery platforms, and to accelerate research and innovation
- Improve TB case finding among all populations.
- Prevent TB transmission and disease progression.
- Improve access to high quality, patient-centered TB, DR-TB and TB/HIV services with SWOP clinics